Jonathan Moss

ORCID: 0000-0002-4589-9174 · 4 papers in corpus
rct 2022
Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT
Health technology assessment (Winchester, England) ·doi:10.3310/ZDEG6110

BACKGROUND: Uterine fibroids are the most common tumour in women of reproductive age and are associated with heavy menstrual bleeding, abdominal discomfort, subfertility and reduced quality of life. For women wishing to retain their uterus …

rct 2021
Uterine artery embolization or myomectomy for women with uterine fibroids: Four-year follow-up of a randomised controlled trial
European journal of obstetrics & gynecology and reproductive biology: X ·doi:10.1016/j.eurox.2021.100139

OBJECTIVE: To examine the quality of life experienced by women with symptomatic uterine fibroids who had been treated with UAE in comparison to myomectomy. We report the four-year follow-up of the FEMME randomised trial. Two-year follow-up …

rct 2019
Randomised trial of two embolic agents for uterine artery embolisation for fibroids: Gelfoam versus Embospheres (RAGE trial)
CVIR endovascular ·doi:10.1186/s42155-018-0044-y

BACKGROUND: Uterine artery embolisation (UAE) is an established treatment option for women with symptomatic uterine fibroids who wish to avoid surgery. However the most efficacious embolic agent remains uncertain. METHODS: We conducted a p…

review 2016
Uterine artery embolization for heavy menstrual bleeding
Women's health (London, England) ·doi:10.2217/whe.15.78

Uterine artery embolization (UAE) as a treatment option for fibroids was first reported by Ravina in 1995. Although rapidly adopted by enthusiasts, many were skeptical and its introduction varied widely across the globe. It was not until ra…